Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Ibrahima DioufCharles B MalpasSifat SharminIzanne RoosDana HorakovaEva Kubala HavrdovaFrancesco PattiVahid ShaygannejadSerkan OzakbasGuillermo IzquierdoSara EichauMarco OnofrjAlessandra LugaresiRaed AlroughaniAlexandre PratMarc GirardPierre DuquetteMurat TerziCavit BozFrancois Grand'MaisonSherif HamdyPatrizia SolaDiana FerraroPierre GrammondRecai TurkogluKatherine BuzzardOlga SkibinaBassem YamoutAyse AltintasOliver GerlachVincent van PeschYolanda BlancoDavide MaimoneJeannette Lechner-ScottRoberto BergamaschiRana KarabudakGerardo IulianoChris McGuiganElisabetta CartechiniMichael BarnettStella HughesMaria José SaClaudio SolaroLudwig KapposCristina Ramo-TelloEdgardo CristianoSuzanne HodgkinsonDaniele SpitaleriAysun SoysalThor PetersenMark SleeErnest ButlerFranco GranellaKoen de GansPamela McCombeRadek AmpapaBart Van WijmeerschAnneke van der WaltHelmut ButzkuevenJulie PrevostL G F SinnigeJose Luis Sanchez-MenoyoSteve VucicGuy LaureysLiesbeth Van HijfteDheeraj KhuranaRichard MacdonellRiadh GouiderTamara Castillo-TriviñoOrla GrayEduardo Aguera-MoralesAbdullah Al-AsmiCameron ShawNorma DeriTalal Al-HarbiYara Dadalti FragosoTünde CsépányAngel Perez SempereIrene Trevino-FrenkJan SchepelFraser MooreTomas KalincikPublished in: European journal of neurology (2023)
DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age.